GlycoMimetics, Inc. (GLYC) Stock Analysis
DELISTED 2025
What happened to GlycoMimetics, Inc. (GLYC) stock?
GlycoMimetics, Inc. (GLYC) no longer trades on public markets. It was delisted in July 2025. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GlycoMimetics, Inc. (GLYC) trades at $15.71. GlycoMimetics, Inc. is a clinical-stage biotechnology company focused on developing glycomimetic drugs for unmet medical needs. Their lead drug, uproleselan, targets acute myeloid leukemia (AML) and other cancers. Market cap: $1.01B, Sector: Healthcare.
Last analyzed: May 6, 2026Analyst Coverage for GLYC: GLYC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GLYC against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
GLYC: 2/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →GlycoMimetics, Inc. (GLYC) Healthcare & Pipeline Overview
GlycoMimetics, Inc. is a clinical-stage biotechnology company specializing in glycomimetic drugs targeting unmet medical needs. Their lead candidate, uproleselan, is in Phase 3 trials for acute myeloid leukemia (AML). With a focus on E-selectin inhibition and collaborations with the National Cancer Institute and Apollomics, they aim to address cancers affecting bone and bone marrow.
What Is the Investment Thesis for GLYC?
GlycoMimetics, Inc. presents a focused investment opportunity within the biotechnology sector, primarily driven by the potential success of uproleselan in treating AML. The ongoing Phase 3 trial for relapsed/refractory AML represents a significant catalyst. Positive trial results could lead to regulatory approval and subsequent commercialization, driving revenue growth. The company's gross margin of 100% indicates strong potential profitability upon commercialization, though the current profit margin of -1363.9% reflects the high costs associated with clinical-stage drug development. Key risks include clinical trial failures, regulatory hurdles, and competition from other AML treatments. Successful development and commercialization of GMI-1359 and other pipeline programs could provide additional upside.
Based on FMP financials and quantitative analysis
GLYC Key Highlights
Market capitalization of $1.01B, reflecting investor confidence in the company's pipeline and potential.
- Gross margin of 100.0%, indicating strong potential profitability upon product commercialization.
- Developing uproleselan, an E-selectin inhibitor, in Phase 3 trial to treat relapsed/refractory AML.
- Collaboration with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687.
- Beta of 1.60, suggesting higher volatility compared to the overall market.
Who Are GLYC's Competitors?
GLYC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| AMGN Amgen Inc. | $442.36 | +4.02% | $239B | 86 |
| GILD Gilead Sciences, Inc. | $143.44 | -2.82% | $178B | 62 |
| VERV Verve Therapeutics, Inc. | $11.13 | +0.27% | $994M | 71 |
| CLYM Climb Bio, Inc. | $17.02 | -1.85% | $975M | 76 |
| CVAC CureVac N.V. | $4.66 | +0.00% | $1.05B | 71 |
| ABUS Arbutus Biopharma Corporation | $4.77 | -4.22% | $942M | 83 |
| ALBO Albireo Pharma, Inc. | $44.15 | +0.00% | $916M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GLYC's Key Strengths?
Novel glycomimetic technology platform.
- Lead drug candidate, uproleselan, in Phase 3 clinical trials.
- Strategic collaborations with the National Cancer Institute and Apollomics.
- Experienced management team with expertise in drug development.
What Are GLYC's Weaknesses?
Clinical-stage company with no currently marketed products.
- High research and development costs.
- Dependence on the success of uproleselan.
- Limited number of employees.
What Could Drive GLYC Stock Higher?
Completion of Phase 3 trial for uproleselan in relapsed/refractory AML.
- Regulatory submission and potential approval of uproleselan by the FDA.
- Advancement of GMI-1359 into clinical trials.
- Expansion of uproleselan to other indications through clinical trials.
What Are the Key Risks for GLYC?
Clinical trial failures for uproleselan or other drug candidates.
- Regulatory delays or rejection of uproleselan by the FDA.
- Competition from other AML treatments.
- Patent expiration and generic competition.
- Dependence on key personnel and strategic collaborations.
What Are the Growth Opportunities for GLYC?
- Uproleselan Commercialization: The successful completion of the Phase 3 trial for uproleselan in relapsed/refractory AML and subsequent regulatory approval could lead to significant revenue generation. Timeline: Potential FDA approval and commercial launch within the next 2-3 years.
- Expansion of Uproleselan to Other Indications: Beyond relapsed/refractory AML, uproleselan has the potential to be used in other AML subtypes and potentially other cancers where E-selectin plays a role. This could significantly expand the addressable market for the drug. The market size for broader AML indications could be substantially larger than the relapsed/refractory segment. Timeline: Clinical trials for other indications could commence within the next 3-5 years.
- Development of GMI-1359: GMI-1359, which targets both E-selectin and a chemokine receptor, represents another growth opportunity for GlycoMimetics. Successful development and commercialization of GMI-1359 for cancers affecting the bone and bone marrow, including solid tumors, could diversify the company's revenue streams. The market for bone and bone marrow cancer treatments is substantial and growing. Timeline: Clinical trials and potential commercialization within the next 5-7 years.
- Advancement of GMI-1687: GMI-1687, an antagonist of E-selectin, is being developed to treat vaso-occlusive crisis. This represents a niche market with significant unmet medical needs. Successful development and commercialization of GMI-1687 could provide GlycoMimetics with a valuable product in this area. The market for vaso-occlusive crisis treatments is relatively small but underserved. Timeline: Clinical trials and potential commercialization within the next 4-6 years.
- Strategic Partnerships and Collaborations: GlycoMimetics' existing collaborations with the National Cancer Institute and Apollomics demonstrate the company's ability to form strategic partnerships. Future collaborations with other pharmaceutical companies or research institutions could provide access to new technologies, funding, and expertise, accelerating the development and commercialization of its pipeline products. The value of such partnerships can be substantial, providing both financial resources and market access.
What Are GLYC's Competitive Advantages?
- Proprietary glycomimetic technology platform.
- Strong intellectual property protection for their drug candidates.
- Clinical-stage pipeline with promising drug candidates.
- Strategic collaborations with leading research institutions.
What Does GLYC Do?
GlycoMimetics, Inc., founded in 2003 and headquartered in Rockville, Maryland, is a clinical-stage biotechnology company dedicated to the discovery and development of novel glycomimetic drugs. These drugs are designed to address significant unmet medical needs arising from various diseases. The company's primary focus is on developing treatments for cancers, particularly acute myeloid leukemia (AML) and other cancers affecting the bone and bone marrow. Their lead drug candidate, uproleselan, is an E-selectin inhibitor currently in Phase 3 clinical trials for relapsed/refractory AML. Uproleselan is used in combination with chemotherapy to improve patient outcomes. In addition to uproleselan, GlycoMimetics is developing GMI-1359, which targets both E-selectin and a chemokine receptor, aiming to treat cancers that affect the bone and bone marrow, including solid tumors. The company also has other programs in its pipeline, including GMI-1687, an antagonist of E-selectin designed to treat vaso-occlusive crisis, and galectin-3 antagonists, which target a carbohydrate-binding protein. GlycoMimetics has established strategic collaborations to advance its research and development efforts, including a cooperative research and development agreement with the National Cancer Institute and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687.
What Products and Services Does GLYC Offer?
- Develop glycomimetic drugs to address unmet medical needs.
- Focus on treating cancers, particularly acute myeloid leukemia (AML).
- Develop E-selectin inhibitors to target cancer cells.
- Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
- Collaborate with research institutions and pharmaceutical companies to advance drug development.
- Seek regulatory approval for their drugs from agencies like the FDA.
How Does GLYC Make Money?
- Develop novel glycomimetic drugs through internal research and development.
- Out-license or co-develop drug candidates with pharmaceutical partners.
- Generate revenue through product sales upon regulatory approval.
- Secure funding through venture capital, public offerings, and strategic partnerships.
What Industry Does GLYC Operate In?
GlycoMimetics operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for AML treatments is growing, driven by an aging population and advancements in diagnostic techniques. Companies like GlycoMimetics are focused on developing targeted therapies to improve patient outcomes and address unmet medical needs. The industry is also witnessing increasing collaborations and partnerships between biotechnology companies and pharmaceutical giants to accelerate drug development and commercialization.
Who Are GLYC's Key Customers?
- Patients with acute myeloid leukemia (AML).
- Patients with cancers affecting the bone and bone marrow.
- Hospitals and oncology clinics.
- Pharmaceutical companies through licensing and collaboration agreements.
How GlycoMimetics, Inc. Is Valued
GlycoMimetics, Inc. carries a market capitalization of $1.01B, placing it in the small-cap category.
Company Profile
GlycoMimetics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Rockville, US. The company is led by CEO Stephanie R. Irish CPA. GLYC has traded publicly since 2014.
Key Financial Metrics
Return on assets is -81.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -28.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 13.78 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -29.6%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
GlycoMimetics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 27.35 places it in the safe zone, indicating low near-term bankruptcy risk.
Forward Outlook
Wall Street analysts project GlycoMimetics, Inc. revenue of about $1.3M for fiscal 2026, with EPS near $-0.03.
GLYC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests those in the know see value, potentially signaling confidence in future prospects.
- The community seems to be buzzing about potential positive clinical trial updates, creating a wave of optimism.
- There's a growing perception that GlycoMimetics is undervalued compared to its peers, sparking interest among value investors.
- Positive sentiment around potential partnerships is building, indicating possible expansion and revenue opportunities.
Bear Case
- Community concerns are surfacing regarding the company's cash runway and potential need for further dilution.
- Negative chatter surrounds recent competitor advancements, raising fears that GlycoMimetics may lose ground.
- Market perception indicates some skepticism about the commercial viability of their lead drug candidate, affecting investor confidence.
- Bearish views are circulating due to uncertainty regarding regulatory approval timelines, casting doubt on near-term revenue generation.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
GLYC Latest News
No recent news available for GLYC.
Leadership: Stephanie R. Irish CPA
Chief Executive Officer
Stephanie R. Irish is the Chief Executive Officer of GlycoMimetics, Inc. Her background as a CPA brings a strong financial perspective to the company's leadership. She oversees the strategic direction and operational execution of the company's drug development programs. Her financial acumen is crucial in managing the company's resources and securing funding for its clinical trials and research activities. She is responsible for managing the company's limited number of employees and ensuring efficient operations.
Track Record: Since becoming CEO, Stephanie R. Irish has focused on advancing the clinical development of uproleselan and GMI-1359. She has overseen the progression of uproleselan into Phase 3 clinical trials and has secured collaborations to support the company's research and development efforts. Her leadership is critical in navigating the complex regulatory landscape and securing funding for the company's operations.
What Investors Ask About GlycoMimetics, Inc. (GLYC) — Healthcare
What happened to GlycoMimetics, Inc. (GLYC) stock?
GlycoMimetics, Inc. (GLYC) no longer trades on public markets. It was delisted in July 2025. The figures below are historical and are not a current quote.
Can I still buy GLYC shares?
No. GLYC stopped trading on public markets in July 2025, so the shares are not available through a broker. Anything you see quoted for GLYC elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before GLYC stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to GlycoMimetics, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does GlycoMimetics, Inc. do?
GlycoMimetics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of glycomimetic drugs. These drugs are designed to address unmet medical needs, particularly in the treatment of cancers. Their lead drug candidate, uproleselan, is an E-selectin inhibitor currently in Phase 3 clinical trials for relapsed/refractory acute myeloid leukemia (AML).
What do analysts say about GLYC stock?
Analyst coverage of GlycoMimetics, Inc. (GLYC) typically focuses on the potential of uproleselan and the company's pipeline. Valuation metrics often consider the probability of success for uproleselan in clinical trials and the potential market size for AML treatments. Growth considerations include the expansion of uproleselan to other indications and the development of GMI-1359.
What are the main risks for GLYC?
The main risks for GlycoMimetics, Inc. include the potential for clinical trial failures, regulatory hurdles, and competition from other AML treatments. As a clinical-stage company, GlycoMimetics is heavily reliant on the success of its drug candidates, particularly uproleselan. Clinical trial failures or regulatory delays could significantly impact the company's value.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Clinical trial outcomes are inherently uncertain.
- Market estimates are based on industry reports and analyst projections.